Tomasz Beer, MD, FACP | Authors


Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPC

April 29, 2014

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.